Who are we ?
Groff North America (Groff NA) is on a mission to help unlock the tremendous potential of Cannabis-based medicines in the U.S and overseas. Having received authorization from the DEA to grow 100% federally-legal Cannabis, we now have a unprecidented pathway to expand the research, development and manufacture of Cannabis therapeutics.
DEA SCHEDULE I REGISTRATIONS
In 2021, Groff NA was awarded the following Suite of schedule I registrations:
- Schedule I Bulk Manufacturing
Bulk Manufacture registration allows for the cultivation, extraction, and processing of federally-legal Cannabis.
- Schedule I Marijuana Non-Bulk Manufacturing (Patient Dose)
Non-Bulk Manufacturing (Patient Dose Form) registration allows Groff NA to take Cannabis grown under the Bulk Manufacturing registration and produce precise dosed forms for clinical trials and for FDA-approved drugs.
- Schedule I Importer
Importer registration allows Groff NA to import Cannabis flower, genetics, and extracts from anywhere in the world for use in our US operations.
- Schedule I Exporter
Exporter registration allows Groff NA to export Cannabis flower and Cannabis preparations to any of the 150+ signatory countries in the UN Single Convention on Narcotics.
- Schedule I Researcher
Researcher registration allows Groff NA to conduct its own research on Cannabis based therapies. This also allows Groff NA to collaborate with researchers working on new Cannabis- based drug development and scientific advancement.
- Schedule I Analytical Lab
Analytical Lab allows Groff NA to commercially test Cannabis at the highest standards possible.